CytoMed Therapeutics Limited (GDTC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GDTC SEC filings page.
CytoMed Therapeutics Limited (GDTC) reported $252K in revenue for fiscal year 2025, up 395.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is expanding from a tiny base, but losses and operating cash use still define the business’s economics.
The key cash-conversion pattern is that capital spending fell from$1.0M to$496K , yet free cash flow worsened rather than improved. That combination indicates deterioration came mainly from ongoing operations, not heavier reinvestment in assets.
Revenue nearly quintupled between FY2024 and FY2025, but the net loss still reached
The balance sheet is lightly funded by long-term debt: it was only
Financial Health Signals
CytoMed Therapeutics Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CytoMed Therapeutics Limited passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
CytoMed Therapeutics Limited reported a net loss of $3.1M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
CytoMed Therapeutics Limited held $1.6M in cash against $42K in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
GDTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
GDTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2410-K | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|
| Total Assets | $6.2M-15.7% | $7.4M-21.4% | $9.4M+140.4% | $3.9M |
| Current Assets | $2.8M-35.1% | $4.4M-42.6% | $7.7M+311.3% | $1.9M |
| Cash & Equivalents | $1.6M-55.4% | $3.7M-19.8% | $4.6M+280.5% | $1.2M |
| Accounts Receivable | $1.2M+61.6% | $754K-9.7% | $835K+22.4% | $682K |
| Total Liabilities | $880K+17.4% | $749K-12.1% | $853K-75.4% | $3.5M |
| Current Liabilities | $551K+24.2% | $444K-18.3% | $543K-82.5% | $3.1M |
| Non-Current Liabilities | $328K+7.5% | $305K-1.2% | $309K-12.9% | $355K |
| Long-Term Debt | $42K+146.6% | $17K | N/A | $5K |
| Total Equity | $5.3M-19.5% | $6.6M-22.3% | $8.5M+1848.5% | $437K |
| Retained Earnings | -$14.6M-34.7% | -$10.9M-16.3% | -$9.3M-52.8% | -$6.1M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill.
GDTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
GDTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CytoMed Therapeutics Limited GDTC | FY2025 | $252K | -$3.1M | N/A | $10.6M | — |
| FibroBiologics, Inc. FBLG | FY2025 | N/A | -$18.6M | N/A | $7.7M | — |
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $1.7M | 42/100 |
| Lixte Biotechnology Holdings, Inc. LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
| Neuraxis, Inc. NRXS | FY2025 | $3.6M | -$7.8M | N/A | $85.0M | 43/100 |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $240.8M | 67/100 |
Where CytoMed Therapeutics Limited Ranks
Frequently Asked Questions
What is CytoMed Therapeutics Limited's annual revenue?
CytoMed Therapeutics Limited (GDTC) reported $252K in total revenue for fiscal year 2025. This represents a 395.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CytoMed Therapeutics Limited's revenue growing?
CytoMed Therapeutics Limited (GDTC) revenue grew by 395.9% year-over-year, from $51K to $252K in fiscal year 2025.
Is CytoMed Therapeutics Limited profitable?
No, CytoMed Therapeutics Limited (GDTC) reported a net income of -$3.1M in fiscal year 2025.
How much debt does CytoMed Therapeutics Limited have?
As of fiscal year 2025, CytoMed Therapeutics Limited (GDTC) had $1.6M in cash and equivalents against $42K in long-term debt.
What is CytoMed Therapeutics Limited's return on equity (ROE)?
CytoMed Therapeutics Limited (GDTC) has a return on equity of -58.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CytoMed Therapeutics Limited's free cash flow?
CytoMed Therapeutics Limited (GDTC) recorded an outflow of $3.4M in free cash flow during fiscal year 2025. This represents a -12.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CytoMed Therapeutics Limited's operating cash flow?
CytoMed Therapeutics Limited (GDTC) recorded an outflow of $2.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CytoMed Therapeutics Limited's total assets?
CytoMed Therapeutics Limited (GDTC) had $6.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CytoMed Therapeutics Limited's capital expenditures?
CytoMed Therapeutics Limited (GDTC) invested $496K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is CytoMed Therapeutics Limited's current ratio?
CytoMed Therapeutics Limited (GDTC) had a current ratio of 5.17 as of fiscal year 2025, which is generally considered healthy.
What is CytoMed Therapeutics Limited's debt-to-equity ratio?
CytoMed Therapeutics Limited (GDTC) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CytoMed Therapeutics Limited's return on assets (ROA)?
CytoMed Therapeutics Limited (GDTC) had a return on assets of -50.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CytoMed Therapeutics Limited's P/E ratio?
CytoMed Therapeutics Limited (GDTC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $10.6M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CytoMed Therapeutics Limited's price-to-sales ratio?
CytoMed Therapeutics Limited (GDTC) trades at 42.1x sales, its market capitalization divided by revenue of $252K revenue, FY2025. The market capitalization is $10.6M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CytoMed Therapeutics Limited's Piotroski F-Score?
CytoMed Therapeutics Limited (GDTC) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CytoMed Therapeutics Limited's earnings high quality?
CytoMed Therapeutics Limited (GDTC) reported a net loss of $3.1M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.